A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
Clinical trial NCT04603287 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04603287
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-17
- Primary completion
- 2025-12-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.